Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial
Dean Follmann, Holly E. Janes, Olive D. Buhule, Honghong Zhou, Bethany Girard, Kristen Marks, Karen Kotloff, Michaël Desjardins, Lawrence Corey, Kathleen M. Neuzil, Jacqueline M. Miller, Hana M. El Sahly, Lindsey R. Baden
doi: https://doi.org/10.1101/2022.04.18.22271936
Dean Follmann
1Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
PhDHolly E. Janes
2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
PhDOlive D. Buhule
1Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
PhDHonghong Zhou
3Moderna, Inc., Cambridge, MA, USA
PhDBethany Girard
3Moderna, Inc., Cambridge, MA, USA
PhDKristen Marks
4Weill Cornell Medicine, New York, NY, USA
MDKaren Kotloff
5Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA
MDMichaël Desjardins
6Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
7Division of Infectious Diseases, Centre hospitalier de l’Université de Montréal, Montreal, QC, Canada
MDLawrence Corey
2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
8Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA
MDKathleen M. Neuzil
5Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA
MD, MPHJacqueline M. Miller
3Moderna, Inc., Cambridge, MA, USA
MDHana M. El Sahly
9Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA
MDLindsey R. Baden
6Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
MDArticle usage
Posted April 19, 2022.
Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial
Dean Follmann, Holly E. Janes, Olive D. Buhule, Honghong Zhou, Bethany Girard, Kristen Marks, Karen Kotloff, Michaël Desjardins, Lawrence Corey, Kathleen M. Neuzil, Jacqueline M. Miller, Hana M. El Sahly, Lindsey R. Baden
medRxiv 2022.04.18.22271936; doi: https://doi.org/10.1101/2022.04.18.22271936
Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial
Dean Follmann, Holly E. Janes, Olive D. Buhule, Honghong Zhou, Bethany Girard, Kristen Marks, Karen Kotloff, Michaël Desjardins, Lawrence Corey, Kathleen M. Neuzil, Jacqueline M. Miller, Hana M. El Sahly, Lindsey R. Baden
medRxiv 2022.04.18.22271936; doi: https://doi.org/10.1101/2022.04.18.22271936
Subject Area
Subject Areas
- Addiction Medicine (372)
- Allergy and Immunology (690)
- Anesthesia (184)
- Cardiovascular Medicine (2756)
- Dermatology (235)
- Emergency Medicine (414)
- Epidemiology (12404)
- Forensic Medicine (10)
- Gastroenterology (784)
- Genetic and Genomic Medicine (4264)
- Geriatric Medicine (396)
- Health Economics (700)
- Health Informatics (2760)
- Health Policy (1020)
- Hematology (370)
- HIV/AIDS (880)
- Medical Education (404)
- Medical Ethics (112)
- Nephrology (454)
- Neurology (4046)
- Nursing (216)
- Nutrition (600)
- Oncology (2132)
- Ophthalmology (606)
- Orthopedics (251)
- Otolaryngology (313)
- Pain Medicine (256)
- Palliative Medicine (77)
- Pathology (478)
- Pediatrics (1149)
- Primary Care Research (470)
- Public and Global Health (6659)
- Radiology and Imaging (1446)
- Respiratory Medicine (886)
- Rheumatology (421)
- Sports Medicine (353)
- Surgery (465)
- Toxicology (57)
- Transplantation (192)
- Urology (171)